[{"Physician_Profile_ID": "125678", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "ELI LILLY AND COMPANY", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IN", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000088", "Total_Amount_of_Payment_USDollars": "1522.48", "Date_of_Payment": "10/01/2014", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "144086310", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED 24-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS", "Research_Information_Link": "https://clinicaltrials.gov/ct2/show/NCT02349295", "Context_of_Research": "THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."}, {"Physician_Profile_ID": "125678", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Eli Lilly and Company", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IN", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000088", "Total_Amount_of_Payment_USDollars": "529.15", "Date_of_Payment": "11/23/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "263816364", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A PHASE 3, MULTICENTER STUDY WITH A 36-WEEK OPEN-LABEL PERIOD FOLLOWED BY A RANDOMIZED DOUBLE-BLIND WITHDRAWAL PERIOD FROM WEEK 36 TO WEEK 104 TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- 80 MG EVERY 2 WEEKS IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS", "Research_Information_Link": "https://clinicaltrials.gov/ct2/show/NCT02584855", "Context_of_Research": "The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."}, {"Physician_Profile_ID": "125678", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Janssen Research & Development, LLC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005592", "Total_Amount_of_Payment_USDollars": "30.00", "Date_of_Payment": "01/20/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "263669958", "Name_of_Associated_Covered_Drug_or_Biological1": "SIRUKUMAB", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Vaccine Response Substudy of: A Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy", "Research_Information_Link": "", "Context_of_Research": ""}]